Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › remdesivir

remdesivir

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of remdesivir

25 trials tracked of remdesivir: 19 in phase 3 or 4 and 16 with published results. The most-cited published study has 1913 citations.

25Trials tracked
19Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 4 1 Phase 3 18 Phase 2 3 Other / NA 3
  1. Phase 3 Adaptive COVID-19 Treatment Trial 2 (ACTT-2) Completed · 1,913 cited
  2. Phase 3 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease Completed · 1,604 cited
  3. Phase 3 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) Completed · 1,436 cited
  4. Phase 3 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Completed · 1,276 cited
  5. Phase 3 LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) Completed · 461 cited
  6. Phase 3 Adaptive COVID-19 Treatment Trial 3 (ACTT-3) Completed · 306 cited
Show 19 more trials
  1. Phase 3 BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) Completed · 194 cited
  2. Phase 3 Adaptive COVID-19 Treatment Trial (ACTT) Completed · 152 cited
  3. Phase 3 Adaptive COVID-19 Treatment Trial 4 (ACTT-4) Completed · 152 cited
  4. Phase 3 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) Completed · 127 cited
  5. Phase 3 ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 Completed · 109 cited
  6. Phase 3 VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) Completed · 76 cited
  7. Phase 3 Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Completed · 74 cited
  8. Phase 3 Immune Modulators for Treating COVID-19 Completed · 67 cited
  9. Phase 3 MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) Completed · 31 cited
  10. Phase 4 Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients Completed · 10 cited
  11. Phase 3 A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia Completed
  12. Phase 3 Study of Remdesivir in Participants Below 18 Years Old With COVID-19 Completed
  13. Phase 3 Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) Completed
  14. Phase 2 ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19 Completed
  15. Phase 2 ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 Completed
  16. Phase 2 ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 Completed
  17. N/A Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir. Completed
  18. N/A SARS-CoV-2 Human Challenge Characterisation Study Completed
  19. N/A PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Remdesivir reduces COVID-19 hospitalization or death risk in high-risk outpatients
Infectious Disease RCT
Remdesivir reduces COVID-19 hospitalization or death risk in high-risk outpatients Remdesivir may cut hospitalization risk for high-risk COVID outpatients
This Bayesian reanalysis of a Phase 3 RCT in high-risk outpatients with COVID-19 found a posterior median hazard ratio of 0.13 for COVID-19-…
A reanalysis of trial data suggests remdesivir sharply lowers the chance of hospitalization or death for high-risk COVID patients treated at…
Apr 23, 2026
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes
Pulmonology & Critical Care Cohort
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes What helps hospitalized COVID-19 patients survive? A new model offers clues
This cohort study of 711 hospitalized subjects with coronavirus evaluated antiviral, antiretroviral, and immunosuppressive treatments.
When COVID-19 hits hard, doctors need better tools to predict who might get worse.
medRxiv Apr 16, 2026
Observational report describes racial and ethnic disparities in receiving COVID-19 treatment medications in the US
Infectious Disease
Observational report describes racial and ethnic disparities in receiving COVID-19 treatment medications in the US Report describes racial and ethnic disparities in receiving COVID-19 treatment medications
An observational report from the United States described racial and ethnic disparities in the receipt of medications for COVID-19 treatment.
A new report describes racial and ethnic disparities in receiving medications for COVID-19 treatment in the United States.
CDC Apr 6, 2026